| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 21 | 2021 | 378 | 3.770 |
Why?
|
| Hypertension | 20 | 2021 | 1024 | 2.850 |
Why?
|
| Blood Pressure | 20 | 2021 | 901 | 2.710 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 429 | 1.820 |
Why?
|
| Blood Pressure Determination | 8 | 2019 | 108 | 1.650 |
Why?
|
| Cardiology | 3 | 2018 | 110 | 1.490 |
Why?
|
| Ferritins | 15 | 2020 | 51 | 1.470 |
Why?
|
| Hemochromatosis | 20 | 2009 | 70 | 1.460 |
Why?
|
| American Heart Association | 3 | 2018 | 92 | 1.180 |
Why?
|
| Weight Loss | 14 | 2021 | 493 | 1.130 |
Why?
|
| Transferrin | 12 | 2020 | 33 | 1.130 |
Why?
|
| Histocompatibility Antigens Class I | 17 | 2009 | 59 | 0.910 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2017 | 1523 | 0.820 |
Why?
|
| Membrane Proteins | 17 | 2009 | 268 | 0.820 |
Why?
|
| Iron Overload | 13 | 2009 | 38 | 0.800 |
Why?
|
| Sleep Apnea, Obstructive | 7 | 2021 | 60 | 0.770 |
Why?
|
| Humans | 114 | 2021 | 34474 | 0.740 |
Why?
|
| Middle Aged | 73 | 2021 | 12703 | 0.710 |
Why?
|
| Female | 93 | 2021 | 21490 | 0.670 |
Why?
|
| Aged | 61 | 2021 | 10998 | 0.660 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 9 | 0.640 |
Why?
|
| Dementia | 2 | 2019 | 252 | 0.620 |
Why?
|
| Ethnic Groups | 6 | 2021 | 483 | 0.610 |
Why?
|
| Life Style | 10 | 2021 | 418 | 0.610 |
Why?
|
| Male | 81 | 2021 | 20697 | 0.600 |
Why?
|
| Cardiovascular Diseases | 13 | 2021 | 1209 | 0.580 |
Why?
|
| Advisory Committees | 1 | 2017 | 37 | 0.540 |
Why?
|
| Adult | 47 | 2021 | 10015 | 0.530 |
Why?
|
| Disease Management | 1 | 2017 | 134 | 0.500 |
Why?
|
| Electroconvulsive Therapy | 5 | 2012 | 30 | 0.490 |
Why?
|
| Estrogen Replacement Therapy | 10 | 2008 | 222 | 0.440 |
Why?
|
| United States | 14 | 2020 | 4267 | 0.440 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2018 | 302 | 0.420 |
Why?
|
| Obesity | 10 | 2020 | 1244 | 0.420 |
Why?
|
| Models, Statistical | 4 | 2021 | 193 | 0.380 |
Why?
|
| Polymorphism, Genetic | 5 | 2010 | 189 | 0.380 |
Why?
|
| Mutation | 10 | 2020 | 529 | 0.370 |
Why?
|
| Iron | 9 | 2009 | 121 | 0.360 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 325 | 0.360 |
Why?
|
| Data Interpretation, Statistical | 3 | 2000 | 123 | 0.310 |
Why?
|
| Severity of Illness Index | 16 | 2021 | 922 | 0.300 |
Why?
|
| Genotype | 16 | 2010 | 743 | 0.280 |
Why?
|
| Brain | 5 | 2019 | 1031 | 0.280 |
Why?
|
| Homozygote | 10 | 2009 | 59 | 0.270 |
Why?
|
| Cation Transport Proteins | 2 | 2007 | 24 | 0.270 |
Why?
|
| Treatment Outcome | 13 | 2021 | 3618 | 0.270 |
Why?
|
| Coronary Disease | 5 | 2012 | 239 | 0.270 |
Why?
|
| Mass Screening | 8 | 2009 | 268 | 0.260 |
Why?
|
| Overweight | 5 | 2017 | 288 | 0.260 |
Why?
|
| Psoriasis | 8 | 1999 | 362 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 565 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2007 | 259 | 0.250 |
Why?
|
| Seizures | 3 | 1998 | 67 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 3 | 2009 | 120 | 0.240 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 2366 | 0.240 |
Why?
|
| Postmenopause | 9 | 2009 | 461 | 0.230 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 4150 | 0.230 |
Why?
|
| Coronary Artery Disease | 5 | 2008 | 441 | 0.230 |
Why?
|
| Risk Factors | 14 | 2019 | 4136 | 0.220 |
Why?
|
| Risk Reduction Behavior | 3 | 2018 | 129 | 0.220 |
Why?
|
| European Continental Ancestry Group | 7 | 2009 | 1176 | 0.220 |
Why?
|
| Diet, Reducing | 3 | 2014 | 109 | 0.220 |
Why?
|
| Carbamates | 1 | 2004 | 18 | 0.220 |
Why?
|
| Mental Disorders | 3 | 2003 | 127 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 1386 | 0.220 |
Why?
|
| Metformin | 1 | 2004 | 27 | 0.220 |
Why?
|
| Prevalence | 7 | 2020 | 1034 | 0.200 |
Why?
|
| Piperidines | 1 | 2004 | 141 | 0.200 |
Why?
|
| Cholesterol, HDL | 4 | 2012 | 194 | 0.200 |
Why?
|
| Estrogens, Conjugated (USP) | 5 | 2009 | 159 | 0.200 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 136 | 0.200 |
Why?
|
| Medroxyprogesterone Acetate | 5 | 2009 | 115 | 0.200 |
Why?
|
| Electroencephalography | 4 | 1998 | 76 | 0.200 |
Why?
|
| Internet | 1 | 2005 | 207 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 200 | 0.200 |
Why?
|
| Comorbidity | 4 | 2018 | 596 | 0.190 |
Why?
|
| Canada | 3 | 2020 | 69 | 0.190 |
Why?
|
| Adolescent Health Services | 1 | 2003 | 12 | 0.190 |
Why?
|
| Aftercare | 1 | 2003 | 35 | 0.190 |
Why?
|
| Research Design | 4 | 2003 | 337 | 0.190 |
Why?
|
| Genetic Testing | 5 | 2009 | 99 | 0.190 |
Why?
|
| Mental Health Services | 1 | 2003 | 36 | 0.190 |
Why?
|
| Polysomnography | 7 | 2021 | 41 | 0.190 |
Why?
|
| Suicide, Attempted | 5 | 2001 | 33 | 0.180 |
Why?
|
| Quality of Life | 7 | 2012 | 1032 | 0.170 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 257 | 0.170 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 1607 | 0.170 |
Why?
|
| Cerebrovascular Circulation | 3 | 1998 | 104 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2003 | 260 | 0.160 |
Why?
|
| Exercise | 4 | 2013 | 700 | 0.160 |
Why?
|
| Sleep, REM | 2 | 2017 | 6 | 0.160 |
Why?
|
| Adolescent | 14 | 2021 | 3799 | 0.160 |
Why?
|
| Cognition | 2 | 2020 | 576 | 0.150 |
Why?
|
| Biometry | 1 | 1999 | 14 | 0.150 |
Why?
|
| Echo-Planar Imaging | 1 | 1999 | 15 | 0.150 |
Why?
|
| Cerebral Infarction | 1 | 1999 | 25 | 0.150 |
Why?
|
| Mass Media | 1 | 2019 | 14 | 0.150 |
Why?
|
| Cause of Death | 2 | 2017 | 245 | 0.150 |
Why?
|
| Image Enhancement | 1 | 1999 | 74 | 0.150 |
Why?
|
| Thyroxine | 2 | 2009 | 18 | 0.150 |
Why?
|
| Disabled Persons | 1 | 1999 | 101 | 0.150 |
Why?
|
| Consensus | 1 | 2018 | 91 | 0.140 |
Why?
|
| Risk Assessment | 8 | 2018 | 1506 | 0.140 |
Why?
|
| Lipoproteins | 2 | 2009 | 99 | 0.140 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 612 | 0.140 |
Why?
|
| Patient Care Planning | 2 | 2017 | 58 | 0.130 |
Why?
|
| Sleep | 2 | 2014 | 90 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 230 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 1997 | 55 | 0.130 |
Why?
|
| Infant, Premature, Diseases | 1 | 1997 | 26 | 0.130 |
Why?
|
| Cerebral Hemorrhage | 1 | 1997 | 72 | 0.120 |
Why?
|
| Dental Implantation, Endosseous | 1 | 1996 | 4 | 0.120 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2016 | 18 | 0.120 |
Why?
|
| Dental Implants | 1 | 1996 | 7 | 0.120 |
Why?
|
| Triglycerides | 5 | 2009 | 249 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 803 | 0.120 |
Why?
|
| C-Reactive Protein | 2 | 2010 | 248 | 0.120 |
Why?
|
| Sports Medicine | 1 | 1996 | 28 | 0.120 |
Why?
|
| Mandible | 1 | 1996 | 39 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2017 | 157 | 0.120 |
Why?
|
| Brachial Artery | 2 | 2007 | 76 | 0.120 |
Why?
|
| Vasodilation | 2 | 2007 | 96 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2016 | 135 | 0.110 |
Why?
|
| Scapula | 1 | 1995 | 20 | 0.110 |
Why?
|
| Body Mass Index | 6 | 2016 | 953 | 0.110 |
Why?
|
| Aging | 2 | 1999 | 1010 | 0.110 |
Why?
|
| Time Factors | 6 | 2017 | 2352 | 0.110 |
Why?
|
| Caffeine | 1 | 1994 | 29 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 1997 | 294 | 0.100 |
Why?
|
| Cocaine | 2 | 1995 | 355 | 0.100 |
Why?
|
| Heart Failure | 2 | 2017 | 780 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 274 | 0.100 |
Why?
|
| Intracranial Embolism and Thrombosis | 3 | 1998 | 3 | 0.100 |
Why?
|
| Software | 3 | 2005 | 130 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 3 | 1998 | 58 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2003 | 2461 | 0.100 |
Why?
|
| Estrogens | 2 | 2007 | 210 | 0.090 |
Why?
|
| Shoulder Joint | 1 | 1995 | 141 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 1994 | 303 | 0.090 |
Why?
|
| Depressive Disorder, Major | 1 | 2012 | 41 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2014 | 201 | 0.090 |
Why?
|
| Logistic Models | 4 | 2006 | 808 | 0.090 |
Why?
|
| Internship and Residency | 1 | 1995 | 330 | 0.090 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 117 | 0.090 |
Why?
|
| Potassium, Dietary | 2 | 2001 | 5 | 0.090 |
Why?
|
| Cholesterol | 3 | 2008 | 273 | 0.090 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 153 | 0.090 |
Why?
|
| Sodium, Dietary | 2 | 2001 | 23 | 0.080 |
Why?
|
| Stroke | 2 | 2017 | 700 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2009 | 849 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 984 | 0.080 |
Why?
|
| Child | 7 | 2003 | 2613 | 0.080 |
Why?
|
| International Cooperation | 1 | 2010 | 33 | 0.080 |
Why?
|
| Phenotype | 6 | 2009 | 656 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2010 | 43 | 0.080 |
Why?
|
| Asian Americans | 2 | 2007 | 96 | 0.080 |
Why?
|
| Erythrocyte Count | 1 | 2009 | 4 | 0.080 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2020 | 30 | 0.080 |
Why?
|
| North Carolina | 4 | 2003 | 1612 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2018 | 509 | 0.080 |
Why?
|
| Age Factors | 5 | 2018 | 1261 | 0.080 |
Why?
|
| DNA | 2 | 2008 | 235 | 0.080 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2009 | 70 | 0.070 |
Why?
|
| Indians, North American | 2 | 2006 | 110 | 0.070 |
Why?
|
| Liver Diseases | 2 | 2006 | 75 | 0.070 |
Why?
|
| Hormones | 1 | 2008 | 26 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2009 | 107 | 0.070 |
Why?
|
| Thyrotropin | 1 | 2008 | 9 | 0.070 |
Why?
|
| Observer Variation | 3 | 1998 | 108 | 0.070 |
Why?
|
| Patient Education as Topic | 3 | 2016 | 261 | 0.070 |
Why?
|
| Young Adult | 3 | 2021 | 2825 | 0.070 |
Why?
|
| Adolescent Behavior | 2 | 1999 | 64 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2004 | 318 | 0.070 |
Why?
|
| Albuminuria | 1 | 2009 | 181 | 0.070 |
Why?
|
| Iron-Binding Proteins | 1 | 2007 | 5 | 0.070 |
Why?
|
| Erythrocyte Indices | 1 | 2007 | 4 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 1078 | 0.070 |
Why?
|
| Prognosis | 3 | 2018 | 1603 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2007 | 49 | 0.070 |
Why?
|
| Health Status | 2 | 2016 | 411 | 0.070 |
Why?
|
| Oceanic Ancestry Group | 1 | 2007 | 6 | 0.070 |
Why?
|
| Contraceptive Agents, Female | 1 | 2007 | 15 | 0.060 |
Why?
|
| E-Selectin | 2 | 2008 | 21 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 2 | 1998 | 28 | 0.060 |
Why?
|
| Hospitalization | 3 | 2001 | 500 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 315 | 0.060 |
Why?
|
| Coronary Angiography | 5 | 2008 | 168 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 1997 | 730 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 934 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2007 | 202 | 0.060 |
Why?
|
| Continental Population Groups | 1 | 2007 | 245 | 0.060 |
Why?
|
| Anthropometry | 2 | 2017 | 88 | 0.060 |
Why?
|
| Systole | 2 | 2017 | 103 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 755 | 0.060 |
Why?
|
| African Continental Ancestry Group | 2 | 2005 | 367 | 0.060 |
Why?
|
| Sex Factors | 4 | 2018 | 707 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1288 | 0.060 |
Why?
|
| African Americans | 2 | 2014 | 1435 | 0.060 |
Why?
|
| Forecasting | 2 | 2003 | 153 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 2 | 2002 | 96 | 0.050 |
Why?
|
| Double-Blind Method | 5 | 2007 | 597 | 0.050 |
Why?
|
| Reference Standards | 2 | 2017 | 34 | 0.050 |
Why?
|
| Adaptation, Psychological | 2 | 2003 | 145 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2004 | 212 | 0.050 |
Why?
|
| Nutritional Status | 2 | 2001 | 80 | 0.050 |
Why?
|
| Microcirculation | 3 | 1998 | 72 | 0.050 |
Why?
|
| Utilization Review | 1 | 2003 | 19 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 589 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 439 | 0.050 |
Why?
|
| Patient Selection | 2 | 2003 | 291 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2012 | 480 | 0.050 |
Why?
|
| Factor V | 1 | 2002 | 7 | 0.050 |
Why?
|
| Depressive Disorder | 2 | 2000 | 76 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 548 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2002 | 38 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 49 | 0.050 |
Why?
|
| Gene Frequency | 3 | 2007 | 222 | 0.040 |
Why?
|
| Women's Health | 1 | 2003 | 242 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2017 | 529 | 0.040 |
Why?
|
| Ethanol | 1 | 2003 | 198 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 1998 | 83 | 0.040 |
Why?
|
| Reference Values | 2 | 2014 | 265 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 29 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 260 | 0.040 |
Why?
|
| Problem Solving | 1 | 2001 | 29 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2001 | 801 | 0.040 |
Why?
|
| Heliotherapy | 2 | 1997 | 3 | 0.040 |
Why?
|
| Social Environment | 1 | 2001 | 82 | 0.040 |
Why?
|
| Liver | 1 | 2003 | 510 | 0.040 |
Why?
|
| Histocytochemistry | 2 | 1998 | 35 | 0.040 |
Why?
|
| Alkaline Phosphatase | 2 | 1998 | 44 | 0.040 |
Why?
|
| Medroxyprogesterone | 1 | 2000 | 15 | 0.040 |
Why?
|
| Lipids | 2 | 2000 | 267 | 0.040 |
Why?
|
| Progesterone Congeners | 1 | 2000 | 22 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 72 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 150 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1999 | 52 | 0.040 |
Why?
|
| California | 1 | 1999 | 68 | 0.040 |
Why?
|
| Self Administration | 3 | 1997 | 385 | 0.040 |
Why?
|
| Memory | 1 | 2001 | 216 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 1999 | 75 | 0.040 |
Why?
|
| Waist Circumference | 2 | 2009 | 94 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 236 | 0.040 |
Why?
|
| Placebos | 2 | 2008 | 69 | 0.040 |
Why?
|
| Adolescent, Hospitalized | 1 | 1998 | 2 | 0.040 |
Why?
|
| Acute Disease | 1 | 1999 | 276 | 0.040 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1998 | 4 | 0.040 |
Why?
|
| Suction | 1 | 1998 | 10 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2006 | 819 | 0.040 |
Why?
|
| Sleep Stages | 2 | 2014 | 6 | 0.040 |
Why?
|
| Silicon | 1 | 1998 | 2 | 0.030 |
Why?
|
| Aluminum | 1 | 1998 | 4 | 0.030 |
Why?
|
| Urban Population | 1 | 1998 | 97 | 0.030 |
Why?
|
| Mutation, Missense | 2 | 2008 | 51 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 155 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1999 | 438 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1997 | 14 | 0.030 |
Why?
|
| Receptors, Transferrin | 2 | 2008 | 10 | 0.030 |
Why?
|
| Gastric Acidity Determination | 1 | 1997 | 4 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2008 | 14 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 1997 | 9 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 1998 | 149 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 1997 | 24 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 2007 | 22 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1998 | 83 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2000 | 390 | 0.030 |
Why?
|
| Office Visits | 1 | 2017 | 73 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 306 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 1997 | 23 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1997 | 50 | 0.030 |
Why?
|
| Veins | 1 | 1997 | 35 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 113 | 0.030 |
Why?
|
| Recurrence | 3 | 2008 | 295 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2008 | 194 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2008 | 924 | 0.030 |
Why?
|
| Infant, Premature | 1 | 1997 | 80 | 0.030 |
Why?
|
| Home Nursing | 1 | 1996 | 9 | 0.030 |
Why?
|
| Rural Population | 1 | 1998 | 297 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 1996 | 18 | 0.030 |
Why?
|
| Animals | 6 | 2003 | 8544 | 0.030 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2016 | 5 | 0.030 |
Why?
|
| Alveolectomy | 1 | 1996 | 1 | 0.030 |
Why?
|
| Incisor | 1 | 1996 | 1 | 0.030 |
Why?
|
| Jaw, Edentulous | 1 | 1996 | 2 | 0.030 |
Why?
|
| Bicuspid | 1 | 1996 | 2 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 2 | 2009 | 54 | 0.030 |
Why?
|
| Molar | 1 | 1996 | 4 | 0.030 |
Why?
|
| Alveolar Process | 1 | 1996 | 5 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 1996 | 10 | 0.030 |
Why?
|
| Titanium | 1 | 1996 | 11 | 0.030 |
Why?
|
| Ultraviolet Therapy | 1 | 1996 | 40 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 1996 | 33 | 0.030 |
Why?
|
| Patient Admission | 1 | 1996 | 59 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 1996 | 80 | 0.030 |
Why?
|
| Goals | 1 | 2015 | 36 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2003 | 310 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 210 | 0.030 |
Why?
|
| Apnea | 1 | 2014 | 6 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 1995 | 138 | 0.030 |
Why?
|
| Depression | 2 | 2012 | 458 | 0.030 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 13 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1994 | 16 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 54 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 67 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 87 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 1995 | 121 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 1994 | 103 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1994 | 214 | 0.030 |
Why?
|
| Diet | 2 | 2012 | 418 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 464 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 138 | 0.030 |
Why?
|
| Conditioning, Operant | 1 | 1994 | 125 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 254 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 170 | 0.020 |
Why?
|
| Disease Progression | 2 | 2008 | 633 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 515 | 0.020 |
Why?
|
| Dogs | 3 | 1998 | 130 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 97 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 1994 | 355 | 0.020 |
Why?
|
| Motor Activity | 1 | 1995 | 356 | 0.020 |
Why?
|
| Dopamine | 1 | 1995 | 268 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 1995 | 242 | 0.020 |
Why?
|
| Primary Health Care | 2 | 2006 | 240 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 163 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 372 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 168 | 0.020 |
Why?
|
| Weight Gain | 1 | 2012 | 117 | 0.020 |
Why?
|
| Sodium | 2 | 2001 | 42 | 0.020 |
Why?
|
| Potassium | 2 | 2001 | 40 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 19 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 24 | 0.020 |
Why?
|
| Education | 1 | 2010 | 38 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 49 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 142 | 0.020 |
Why?
|
| North America | 1 | 2009 | 34 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 43 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1994 | 657 | 0.020 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2009 | 13 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2009 | 12 | 0.020 |
Why?
|
| Lipoprotein Lipase | 1 | 2009 | 14 | 0.020 |
Why?
|
| Lipase | 1 | 2009 | 30 | 0.020 |
Why?
|
| Attitude to Health | 2 | 2003 | 161 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 113 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 60 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 43 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 1910 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 2008 | 2 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 1999 | 111 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 2 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2008 | 16 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2008 | 12 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 211 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 257 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 41 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 343 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 168 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2007 | 131 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2007 | 95 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 215 | 0.020 |
Why?
|
| Apoferritins | 1 | 2007 | 4 | 0.020 |
Why?
|
| Arterioles | 2 | 1998 | 17 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 95 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 109 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 560 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 71 | 0.020 |
Why?
|
| Capillaries | 2 | 1998 | 30 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 21 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 43 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2009 | 365 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 925 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 176 | 0.010 |
Why?
|
| Arthritis | 1 | 2005 | 43 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 255 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2007 | 417 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2005 | 124 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 189 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2003 | 8 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2003 | 68 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 46 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 142 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 548 | 0.010 |
Why?
|
| Social Support | 1 | 2003 | 195 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 264 | 0.010 |
Why?
|
| Health Behavior | 1 | 2003 | 246 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 20 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 325 | 0.010 |
Why?
|
| Urinalysis | 1 | 2001 | 27 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2001 | 23 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 113 | 0.010 |
Why?
|
| Affect | 1 | 2001 | 72 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1998 | 3812 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2000 | 66 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2001 | 145 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2000 | 58 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2001 | 214 | 0.010 |
Why?
|
| Virginia | 1 | 1999 | 63 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1998 | 16 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 1998 | 20 | 0.010 |
Why?
|
| Vasculitis | 1 | 1998 | 26 | 0.010 |
Why?
|
| Lasers | 1 | 1998 | 25 | 0.010 |
Why?
|
| Work | 1 | 1997 | 6 | 0.010 |
Why?
|
| Financing, Personal | 1 | 1997 | 6 | 0.010 |
Why?
|
| Absenteeism | 1 | 1997 | 10 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1998 | 114 | 0.010 |
Why?
|
| Family Characteristics | 1 | 1997 | 39 | 0.010 |
Why?
|
| Cost of Illness | 1 | 1997 | 74 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 74 | 0.010 |
Why?
|
| Self Concept | 1 | 1997 | 47 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 1998 | 50 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 52 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 112 | 0.010 |
Why?
|
| Income | 1 | 1997 | 68 | 0.010 |
Why?
|
| Health Expenditures | 1 | 1997 | 71 | 0.010 |
Why?
|
| Self Care | 1 | 1997 | 144 | 0.010 |
Why?
|
| Phytotherapy | 1 | 1996 | 41 | 0.010 |
Why?
|
| Crisis Intervention | 1 | 1996 | 1 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1997 | 126 | 0.010 |
Why?
|
| Personality Assessment | 1 | 1996 | 9 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 267 | 0.010 |
Why?
|
| Arthritis, Psoriatic | 1 | 1996 | 25 | 0.010 |
Why?
|
| Smoking | 1 | 2000 | 544 | 0.010 |
Why?
|
| Vitamins | 1 | 1996 | 75 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1997 | 446 | 0.010 |
Why?
|
| Electrooculography | 1 | 1995 | 2 | 0.010 |
Why?
|
| Arousal | 1 | 1995 | 20 | 0.010 |
Why?
|
| Data Collection | 1 | 1996 | 191 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1997 | 245 | 0.010 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1995 | 5 | 0.010 |
Why?
|
| Skin | 1 | 1997 | 222 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1996 | 81 | 0.010 |
Why?
|
| Homovanillic Acid | 1 | 1995 | 15 | 0.010 |
Why?
|
| Mortality | 1 | 1996 | 127 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1995 | 153 | 0.010 |
Why?
|
| Length of Stay | 1 | 1996 | 335 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1996 | 583 | 0.010 |
Why?
|
| Infant | 1 | 1997 | 1122 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1997 | 1354 | 0.010 |
Why?
|
| Rats | 1 | 1995 | 1946 | 0.010 |
Why?
|